Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Nina D. Wagner-Johnston"'
Autor:
Christopher D. Fletcher, Kevin A. David, Craig A. Portell, Brad S. Kahl, Nina D. Wagner-Johnston, Grzegorz S. Nowakowski, Opeyemi Jegede, Nadia Khan, Lori J. Rosenstein, Jonathon B. Cohen
Publikováno v:
Blood. 138:814-814
Background: Chemoimmunotherapy is considered standard initial therapy for follicular lymphoma (FL) with high tumor burden (HTB). Obinutuzumab and Bendamustine (OB) with maintenance Obinutuzumab (mO) is considered a standard therapy for the frontline
Autor:
Yeonhee Kim, Ian W. Flinn, Richard R. Furman, Nina D. Wagner-Johnston, Nathan Fowler, Thomas E. Boyd, Steven Coutre, Ralph V. Boccia, Sven de Vos, Marshall T. Schreeder, John P. Leonard, Kanti R. Rai, Jacqueline C. Barrientos, Jeff P. Sharman, Wayne R. Godfrey
Publikováno v:
Blood Advances. 1:122-131
Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib in combin
Autor:
Mei Yin C. Polley, Jim Atkins, Sin-Ho Jung, John P. Leonard, Beth Christian, Eric D. Hsi, Travis J. Dockter, Nina D. Wagner-Johnston, Kristie A. Blum, Bruce D. Cheson, Sarah A. Anderson, Nancy L. Bartlett
Publikováno v:
Cancer
Background This multicenter, randomized phase 2 trial evaluated complete responses (CRs), efficacy, and safety with ofatumumab and bendamustine and with ofatumumab, bendamustine, and bortezomib in patients with untreated, high-risk follicular lymphom
Autor:
Koji Izutsu, Takanori Teshima, Marie José Kersten, Peter Borchmann, Joseph P. McGuirk, Ulrich Jaeger, Ranjan Tiwari, Koen van Besien, Harald Holte, Constantine S. Tam, Koji Kato, Stephen Ronan Foley, Edmund K. Waller, Jason R. Westin, Nina D. Wagner-Johnston, Richard T. Maziarz, Stephen J. Schuster, Rakesh Awasthi, Michael R. Bishop, P. Joy Ho, Stephan Mielke, Veronika Bachanova, Gilles Salles, Isabelle Fleury, Lamis K. Eldjerou, Paolo Corradini, Tomasz Lawniczek, John M. Magenau, Charalambos Andreadis, Samantha Jaglowski
Publikováno v:
Blood. 134:2883-2883
Background: Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor (CAR)-T cell therapy that is approved for adult patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). In the phase 2 JULIET trial, pts coul
Autor:
Stephen J. Schuster, Sven de Vos, Ajay K. Gopal, Nina D. Wagner-Johnston, Gilles Salles, Wojciech Jurczak, Guan Xing, Nishan Rajakumaraswamy
Publikováno v:
Blood. 134:4006-4006
Introduction: Marginal zone lymphoma (MZL) and lymphoplasmacytic lymphoma (LPL)/Waldenstrom's macroglobulinemia (WM) comprise approximately 7% and 2%, respectively, of non-Hodgkin's lymphomas (NHL) (Teras 2016). MZL is further subclassified as spleni
Autor:
Johannes Bloehdorn, Eliana Kozin, Craig A. Portell, John P. Leonard, Peter Martin, Nina D. Wagner-Johnston, Kristie A. Blum, Paul M. Barr, Richard R. Furman, Zhengming Chen, Kami J. Maddocks, Jia Ruan, Maurizio DiLiberto, Simon Rule, David J. Iberri, Ewa Chmielowska, Selina Chen-Kiang, Andre Goy, Rebecca Auer, Tycel Phillips, Martin Dreyling, Stephan Stilgenbauer, Katherine Noto, Ranjana H. Advani, Stephen E. Spurgeon, Michael E. Williams, Wojciech Jurczak
Despite unprecedented clinical activity in mantle cell lymphoma (MCL), primary and acquired resistance to ibrutinib is common. The outcomes and ideal management of patients who experience ibrutinib failure are unclear. We performed a retrospective co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0166c670e66796a5570886e26cc3fa3
https://ruj.uj.edu.pl/xmlui/handle/item/96329
https://ruj.uj.edu.pl/xmlui/handle/item/96329
Autor:
Ian W. Flinn, John P. Leonard, Don M. Benson, Steven Coutre, Sven de Vos, Marshall T. Schreeder, Leanne Holes, Stephen E. Spurgeon, Richard R. Furman, Brad S. Kahl, Harriet (Sissy) Peterman, Langdon L. Miller, Dave Johnson, John C. Byrd, Jennifer R. Brown, Thomas Jahn, Nina D. Wagner-Johnston
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 11:S272-S274
Autor:
Gilles Salles, Ian W. Flinn, Betsy Philip, Ajay K. Gopal, Andrew Davies, Paolo Ghia, Bess Sorenson, Andre Goy, Steve Abella, Nina D. Wagner-Johnston
Publikováno v:
Publons
Background: SLL, a subtype of indolent non-Hodgkin's Lymphoma (iNHL), is considered the tissue equivalent of chronic lymphocytic leukemia (CLL); each disease is considered a clinical variation of the same biological entity. SLL is characterized by th
Autor:
Nathan Fowler, Richard R. Furman, Ian W. Flinn, Wayne R. Godfrey, John P. Leonard, Kanti R. Rai, Thomas E. Boyd, Nina D. Wagner-Johnston, Jaqueline C. Barrientos, Ralph V. Boccia, Steven Coutre, Sven de Vos, Marshall T. Schreeder, Leanne Holes, Jeff P. Sharman, Yeonhee Kim
Publikováno v:
Blood. 124:3063-3063
Introduction: PI3K-delta signaling is critical for activation, proliferation and survival of B cells, and is hyperactive in many B-cell malignancies. Idelalisib, a selective oral inhibitor of PI3Kd, demonstrated considerable clinical activity as mono
Autor:
Manish Patel, Greg Coffey, Nina D. Wagner-Johnston, Janet M. Leeds, Ian W. Flinn, Paul A. Hamlin, Donald K. Strickland, Anjali Pandey, John T. Curnutte, Gallia Levy
Publikováno v:
Blood. 124:3103-3103
Introduction: Preclinical studies of the Syk-mediated B-cell receptor pathway and Jak-mediated cytokine pathways have demonstrated a potential therapeutic advantage for the dual inhibition of both Syk and Jak kinases in the treatment of B-cell malign